The switch from lab-scale to industrial-scale AAV production requires deep hands-on expertise in various technological solutions, their limitations, and their suitability for GMP large-scale manufacturing. Direct application of lab-scale process leads to expensive AAV-based products and unnecessarily laborious industrial processes. The complexity and growing demands for controllable critical quality attributes (CQAs), create a challenging blend.
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Latest NewsTargeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta partners with Biotalys
Latest NewsSyngenta has announced to leverage Biotalys’ AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG bags pre-seed financing
Latest NewsPhialogics AG has got a €600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.
Transition to industrial-scale AAV manufacturing
BackgroundThe switch from lab-scale to industrial-scale AAV production requires deep hands-on expertise in various technological solutions, their limitations, and their suitability for GMP large-scale manufacturing. Direct application of lab-scale process leads to expensive AAV-based products and unnecessarily laborious industrial processes. The complexity and growing demands for controllable critical quality attributes (CQAs), create a challenging blend.
Forbion raises €1.35bn across two funds
Latest NewsEuropean life sciences venture capital company Forbion has raised two oversubscribed funds totalling €1.35 bn.
Ariceum Therapeutics extends Series A to €47.75m
Latest NewsGerman radiopharmaceuticals developer Ariceum Therapeutics has raised a further €22.75m extension of its €25m Series A financing announced in June 2022.
Genmab and argenx combine antibody know-how
Latest NewsGenmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.
Adaptyv Biosytems launches protein engineering foundry
Latest NewsSwiss Adaptyv Biosystems Sàrl has launched two fast-feedback tools that allow cheap, rapid and minaturised validation of AI-designed proteins.
High value biopharma process development
BackgroundBiomanufacturing?Implementing high-quality process development that considers GMP manufacturing from the start is critical to reducing costs and timeline disruptions associated with raw material supply chain insecurity, adhering to regulatory compliance, and avoiding process re-design at a later stage.
Researchers activate chemotherapeutics by ultrasound
Latest NewsUltrasound that switches cancer drug on could significantly reduce chemotherapy side effects, German researchers found in preclinical studies.